⌘K

Login Start Free

Home/Filings/4/0000950170-23-067072

4//SEC Filing

King Michael 4

Accession 0000950170-23-067072

CIK 0001833214other

View on SEC.gov Company Profile

Filed

Nov 29, 7:00 PM ET

Accepted

Nov 30, 5:00 PM ET

Size

4.6 KB

Accession

0000950170-23-067072

Insider Transaction Report

Form 4

Period: 2023-11-30

SAB Biotherapeutics, Inc.SABS

CHIEF FINANCIAL OFFICER

Transactions

Purchase
Common Stock
2023-11-30$0.90/sh+5,000$4,500→ 5,000 total

Footnotes (1)

[F1]Represents 5,000 shares of the Issuer's common stock, par value $0.0001 per share, acquired by the reporting person in an open market transaction.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

SAB Biotherapeutics, Inc.

CIK 0001833214

Entity typeother

Related Parties

1

filerCIK 0001998530

Filing Metadata

Form type: 4
Filed: Nov 29, 7:00 PM ET
Accepted: Nov 30, 5:00 PM ET
Size: 4.6 KB

View on SEC.gov